GSK (@GSK) / X

GSK

14.9K posts

GSK

@GSK

We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: gsk.to/socialmedia

London, UK

Joined April 2007

GSK
@GSK
Jul 16
#News for #Investors and #Media: Today marks another step forward for a GSK-developed vaccine candidate. This significant step reinforces our commitment to partnerships that help improve global public health. Learn more: gsk.to/4vymcTG
00:00
GSK
@GSK
Jul 15
#News for #investors and #media: Today we announced the completion of our acquisition of clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio. Find out more: gsk.to/4wIsLE2
00:00
GSK
@GSK
Jul 13
#News for #Media and #Investors: Today we announced interim positive headline results from our phase II trial evaluating one of our immuno-oncology therapies. Learn more: gsk.to/4vZVG6L
00:00
GSK
@GSK
Jul 10
#News for #Investors and #Media: Today, our licensor Hansoh Pharma announced data on an investigational antibody-drug conjugate in our oncology pipeline for cancers with high unmet needs. Learn more: gsk.to/44X0o9i
00:00
GSK
@GSK
Jun 17
#News for #Media and #Investors: The FDA has approved our oral anti-infective for complicated urinary tract infections (cUTIs). With three million cUTIs treated annually in the US, this approval reflects our commitment to innovation in anti-infectives. Learn more:
00:00
GSK
@GSK
Jun 12
#News for #Investors and #Media: Today, we announced that the US FDA and the EMA have granted regulatory designations for one of our therapies for the treatment of VEXAS syndrome. Learn more: gsk.to/4vJGgCT
00:00
GSK
@GSK
Jun 9
#News for #investors and #media: Following today’s agreement to acquire Nuvalent, Inc., our CEO Luke Miels shares why this acquisition is strategically important to our oncology business as we continue to strengthen our pipeline and commitment to patients. Read more from Luke
GSK
@GSK
Jun 9
#News for #investors and #media: We have entered an agreement to acquire clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio. Find out more: gsk.to/4ooHOjy
00:00
GSK
@GSK
May 28
#News for #investors & #media: Today at #EASLCongress, we’re presenting results from a phase III trial in chronic hepatitis B, a disease affecting approximately 240 million people globally. Thank you to everyone involved who made this research possible. 🔗 Learn more:
00:00
GSK
@GSK
May 26
#News for #investors and #media: We're excited to be at #ASCO26 and #EHA2026, where we will share data on how we're delivering a meaningful impact for cancer patients today while innovating for tomorrow. Learn more: gsk.to/4wPL9f1
00:00
GSK
@GSK
May 18
#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been approved for an expanded population by the Japanese Ministry of Health, Labour and Welfare (MHLW). Learn more: gsk.to/3PKzP3i
00:00
GSK
@GSK
May 15
At #ATS2026, we're sharing findings from 33 research projects across our portfolio of inhaled therapies and biologics – reflecting our ambitious treatment goals, moving beyond symptom control to transform outcomes for people living with chronic respiratory diseases like asthma
00:00
GSK
@GSK
May 6
#News for #investors and #media: At #ATS2026, we’ll be presenting data across 33 abstracts to highlight our research as we work to redefine respiratory care. gsk.to/42ejQxd
00:00
GSK
@GSK
Apr 29
News for #Investors and #Media Explore the key highlights from our Q1 2026 results announcement ⤵️ Find out more: gsk.to/4uelV7Y $GSK
Q1 results 2026
Q1 results 2026
Q1 results 2026
Q1 results 2026
Q1 results 2026
Q1 results 2026
From gsk.com